STATOBEX Drug Patent Profile
✉ Email this page to a colleague
When do Statobex patents expire, and when can generic versions of Statobex launch?
Statobex is a drug marketed by Teva and is included in three NDAs.
The generic ingredient in STATOBEX is phendimetrazine tartrate. There are five drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the phendimetrazine tartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Statobex
A generic version of STATOBEX was approved as phendimetrazine tartrate by VIRTUS on December 31st, 1969.
Summary for STATOBEX
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 21 |
Patent Applications: | 1,999 |
Formulation / Manufacturing: | see details |
DailyMed Link: | STATOBEX at DailyMed |
US Patents and Regulatory Information for STATOBEX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva | STATOBEX | phendimetrazine tartrate | CAPSULE;ORAL | 085507-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Teva | STATOBEX | phendimetrazine tartrate | TABLET;ORAL | 086013-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Teva | STATOBEX-G | phendimetrazine tartrate | TABLET;ORAL | 085095-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |